论文部分内容阅读
采用免疫组织化学 (IHC)和 RNA聚合酶链反应 (RT- PCR)方法检测了 41例卵巢恶性肿瘤 ,2 0例卵巢良性肿瘤和 2 1例正常卵巢组织 nm2 3、CD44 V蛋白的表达 ,以探讨 nm2 3、CD44 V基因在卵巢恶性肿瘤组织中的表达及其临床意义。结果 :(1)卵巢恶性肿瘤组织 nm2 3,CD44 V表达阳性率明显高于卵巢良性肿瘤和正常卵巢组织 (P <0 .0 1)。 (2 ) ～ 期患者 nm2 3阳性表达高于 ～ 期患者 (P <0 .0 1) ,CD44 V阳性表达率则是 ～ 期低于 ～ 期患者 (P <0 .0 1)。 (3)原发灶 nm2 3蛋白的阳性表达率明显高于转移灶 ,而 CD44 V则是转移灶的阳性表达率高于原发灶 (P <0 .0 1)。 (4 ) nm2 3,CD44 V阳性表达与病理分级及病理类型无显著性差异 (P >0 .0 5 )。 (5 ) nm2 3阳性表达 ,CD44 V阴性表达的患者近期疗效好(P <0 .0 5 )。结果提示 :nm2 3、CD44 V阳性表达与卵巢恶性肿瘤转移、浸润以及近期疗效有关 ,对它的检测有助于判断预后
Immunohistochemical (IHC) and RNA polymerase chain reaction (RT-PCR) methods were used to detect the expression of nm23 and CD44V proteins in 41 cases of ovarian malignant tumors, 20 cases of benign ovarian tumors and 21 cases of normal ovarian tissues. To investigate the expression of nm23 and CD44V in ovarian malignant tumors and its clinical significance. RESULTS: (1) The positive rate of nm23 and CD44V expression in malignant ovarian tissue was significantly higher than that in ovarian benign tumors and normal ovarian tissues (P < 0.01). (2) The positive expression rate of nm23 in patients with stage ~ was higher than that in stage ~ (P <0.01), and the positive rate of CD44V was lower than that in stage ~ ~ (P < 0.01). (3) The positive expression rate of nm23 protein in primary tumors was significantly higher than that in metastatic tumors, while the positive expression rate of CD44V in metastatic tumors was higher than that in primary tumors (P < 0.01). (4) There was no significant difference between nm23, CD44V positive expression and pathological grade and pathological type (P > 0.05). (5) The positive expression of nm23 was positive in patients with negative CD44V expression (P < 0.05). The results suggest that the positive expression of nm23 and CD44V is related to the metastasis, infiltration, and short-term therapeutic effects of malignant ovarian tumors. The detection of nm23 and CD44V is helpful to determine the prognosis.